Nisa Investment Advisors
CDAK

Nisa Investment Advisors’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Nisa Investment Advisors’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,190
Closed -$7K – 2546
2022
Q1 		$7K Buy
+1,190
New +$7.47K ﹤0.01% 2271

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Nisa Investment Advisors's CDAK Position: Q2 2022 in Review

Nisa Investment Advisors sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2022, closing a stake of 1,190 shares — an estimated $7K sold.

Nisa Investment Advisors first reported a position in CDAK in Q1 2022 and held it in 1 quarter. The position peaked at $7K in Q1 2022. 49 funds tracked by Wall St. Rank hold CDAK as of Q2 2022.

  • Nisa Investment Advisors reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Nisa Investment Advisors sold 1,190 Codiak BioSciences, Inc. Common Stock shares in Q2 2022, an estimated $7K.
  • Nisa Investment Advisors first reported a position in Codiak BioSciences, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Nisa Investment Advisors's Codiak BioSciences, Inc. Common Stock position peaked at $7K in Q1 2022.
  • 49 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2022.

Based on Nisa Investment Advisors's 13F filing for Q2 2022, filed 3 Aug 2022.